Key Takeaways
- • Novartis has terminated its discovery-stage collaboration with BioArctic, according to Endpoints News, per the publisher summary of the newsletter.
- • The newsletter also reports that two venture capital firms have raised inaugural funds, though the source excerpt does not name the firms or fund sizes.
- • Additional items cover Teva, Ultragenyx and Specific Biologics, but the available excerpt provides no detail on those stories.
Summary
Swiss pharmaceutical company Novartis has ended its discovery-stage collaboration with BioArctic, the Swedish biotechnology firm, according to Endpoints News. The publisher summary indicates the pact was cancelled, but the available text is truncated and does not disclose the financial terms, deal value, or the rationale behind the decision.
The same Endpoints News edition reports that two venture capital firms have closed inaugural funds. The available excerpt does not identify the managers, target sizes, or final fund closes, so no further figures can be confirmed from this source. Readers seeking fund-level detail should consult the full Endpoints article.
The newsletter also briefly references news involving Teva, Ultragenyx and Specific Biologics. The excerpt contains no substantive detail on these items beyond their mention in the headline and summary.
The same Endpoints News edition reports that two venture capital firms have closed inaugural funds. The available excerpt does not identify the managers, target sizes, or final fund closes, so no further figures can be confirmed from this source. Readers seeking fund-level detail should consult the full Endpoints article.
The newsletter also briefly references news involving Teva, Ultragenyx and Specific Biologics. The excerpt contains no substantive detail on these items beyond their mention in the headline and summary.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.